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Abstract
Purpose: In this study, we asked the question of whether non-invasive (NI) extendible bone tumour implants are as
reliable and reduce infection when compared with patients who received a minimally invasive (MI) extendible implant.
Methods: Forty-two NI extendible bone tumour implants were investigated at a mean follow-up of 22 months (range,
1–87 months) and 63 MI implants at a mean follow-up of 49 months (range, 1–156 months). Results: Kaplan–Meier
analysis showed that the probability of MI implant survival was 58.8% compared with 78.6% in NI patients. No significant
difference between these two patient groups was found. Infection was the main reason for failure in the MI implant group
where nine (35%) implants were revised. However, only one (11%) NI implant was revised for infection (p¼ 0.042). None
of the NI implants failed due to aseptic loosening; however, six (23%) MI implants were revised for aseptic loosening of the
intramedullary stem. Four (15%) of the failed MI implants were revised due to full extension and five (56%) of failed NI
implants were replaced as the implant had been fully extended where the patient still required growth. Conclusion:
Where possible, an NI massive prosthesis should be used in this patient group. Our results suggest that MI prostheses
should be infrequently used due to the high incidence of infection. Lengthening of NI prostheses is painless, can be carried
out in the clinic and is more cost-effective. However, further work is required to increase the amount of growth potential
available in these implants.
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Introduction
Skeletally immature patients diagnosed with bone cancer
are candidates for limb salvage surgery using an extendible
prosthesis. Resection of the bone tumour often involves
removing an epiphyseal growth plate, reducing growth of
the affected limb. The concept of extendible endoprosthetic
replacements was first introduced in Stanmore, England, in
1976 and has been in use since 1983.1 Extendible devices
offer children near normal development and overcome leg-
length discrepancy benefiting functional restoration, rapid
rehabilitation and quality of life improvement. Minimally
invasive (MI) extendible prostheses were designed and
introduced in the early 1990s with intramedullary stem
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fixation and a screw extension mechanism within the shaft
of the implant. Extension of the device was produced by
making a small skin incision and inserting an Allen key into
the screw mechanism that when turned, extended the
implant. The main disadvantage of using MI devices is
the open surgical procedure that is required to lengthen the
implants and the younger the child, the more lengthening
procedures are needed. The risk of deep infection increases
with the number of surgical procedures and is one of the
most devastating complications in bone tumour endopros-
thetic surgery.2 Additional complications associated with
multiple surgical procedures for limb lengthening are
increased exposure to anaesthetics, ankylosis, nerve dam-
age, soft tissue damage and amputation.3 Often with the use
of MI prostheses, the limb is over extended to reduce the
number of surgical procedures.
As a result, non-invasive (NI) growing implants have
been developed and these include the Phenix prosthesis4
and the Stanmore NI growing prosthesis.5,6 These NI
extendable prostheses can be lengthened without the need
for repeated surgery. The Juvenile Tumour System (Stan-
more Implants, Elstree, UK) introduced in 2002 as an NI
implant combines a magnetic disc, a gearbox and a drive
screw, where lengthening is controlled using electromag-
netic induction.7 Once implanted, the leg is placed within
the centre of a circular external rotating magnetic field,
which synchronizes with and turns a magnetic disc located
in the shaft of the prosthesis. The magnetic disc drives the
gearbox that lengthens the prosthesis at a controlled rate of
0.23 mm per minute.8 The Stanmore NI extendable pros-
thesis can be lengthened in small increments without the
need for surgical intervention. The aim of this study was to
investigate the effectiveness of the Stanmore MI and NI
extendible prosthesis inserted into patients over a 16-year
period between 1994 and 2010.
Materials and method
Between 1994 and 2010, 105 limb salvage surgeries using
MI and NI extendible growing prostheses were performed
on skeletally immature patients. Sixty-three patients (31
male and 32 female) received an MI prosthesis and 42
(23 male and 19 female) received an NI implant. MI pros-
theses were implanted between 1994 and 2009 and NI
prostheses between 2002 and 2010. All surgeries were per-
formed for primary bone tumour treatment where osteosar-
coma was the most common diagnosis. Twenty-nine
patients (69.0%) who received an NI implant and 54/63
(85.7%) MI patients were diagnosed with osteosarcoma.
All remaining patients were treated for Ewing’s sarcoma
(13 NI patients and 9 MI patients). The mean MI patient
age was 11.67 years (range, 4–16 years) and NI, 10.09
years (range, 5–18 years). Patients in the MI group were
followed up at a mean of 49 months (range, 1–156 months)
and patients in the NI group, 22 months (range, 1–87
months). Sixty-one distal femoral, 21 proximal tibial, 15
proximal femoral, 4 proximal humeral, 2 mid-femoral and
2 total femoral implants were investigated. Each patient
received a unilateral implant with 57/105 (54.3%) inserted
into the right limb and 48/105 (45.7%) into the left. The
mean amount (with standard error) of bone resected in NI
patients was 202.48+ 8.13 mm and 162.46+ 6.94 mm in
MI patients. Depending on bone quality and surgical
choice, implants were either cemented or uncemented
(35.7% NI and 49.2% MI implants were cementless
devices) and all surgeries were performed at a single insti-
tution. No patients were recalled and all data were obtained
from the medical records. This study was approved by the
Royal National Orthopaedic Hospital Institutional Review
Board (SE10.017), where appropriate patients received
neoadjuvant chemotherapy and all met the criteria for limb
salvage.
All prostheses were manufactured on a customized,
case-by-case basis. The extension shaft and intramedullary
stem were made from titanium alloy (Ti 318, Ti6Al4V),
and, when indicated, the stem was shaped to follow the
natural curvature of the bone. All NI and MI implants that
involved replacement of the knee joint used a SMILES™
rotating hinge total joint (Stanmore Implants). A hydroxya-
patite collar, which has previously been shown to enhance
osteointegration and bony bridging at the transection site,9
was located adjacent to the transection site and shoulder of
the implant in all patients. The MI implant design consisted
of a hollow extension tube that incorporated an extension
module manufactured from CoCrMo alloy. The extension
module consisted of a telescopic worm wheel screw gear-
ing mechanism that operated with an Allen key. In the MI
group, the lengthening procedure required access to the
gearing mechanism, which was accomplished through a
small skin incision made under general anaesthesia. The
Stanmore NI extendible implant has been previously
described5–8 and extension was undertaken in the outpati-
ent clinic without anaesthesia, using electromagnetic
induction of a magnet-driven gearbox within the implant
at a rate of 0.23 mm/min at a power of 50 or 100 V. In the
NI implant group, the time taken to lengthen the implant
was dependent on the discrepancy in leg-length and the site
of implantation.
Statistical analysis
Failure was defined as the need for revision of the compo-
nent and conversion to a different prosthesis. In the NI
group, the inability to lengthen was recorded as having a
failed gearbox. In the MI implant group, the inability to
lengthen was recorded as having a failed extension
mechanism. Prostheses with collapsed lengthening
mechanisms were listed as failed and recorded as collapsed
prostheses. Implants revised due to full extension were also
recorded as endoprosthetic failure; however, during revi-
sion surgery, only the implant shaft was replaced leaving
the intramedullary stem fixation undisturbed. Implant
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loosening secondary to infection was classified as a failure;
however, amputation due to local recurrence and irreversi-
ble ischemia were not included in the implant survivorship
analysis as these were unrelated to the durability of the
prosthesis. The duration of follow-up was from the time
of surgery to the time of the latest evaluation. Implant
survival was calculated using Kaplan–Meier analysis using
overall prosthetic revision and failure due to infection and
full extension as the end points. The number of implants
that failed due to aseptic loosening was also recorded.
Cases without failure were censored either at the time of
death or on the date of the last follow-up. The Mantel–Cox
log-rank test was used to compare implant survivorship
where a p value of <0.05 was considered significant. All
analyses were performed using SPSS software (version
17.0; SPSS, Chicago, Illinois, USA).
Results
Five MI patients died of metastatic disease and a sixth MI
patient died (6.7%) following cardiac arrest. In the NI
group, one patient died of metastatic disease. Twenty-
five of the 63 (39.7%) MI implants inserted were revised
(Figure 1) and 9 of the 42 (21.4%) NI implants were
revised (Figure 2).
Infection
There were 13 MI prosthetic infections compared to 4 NI
infections although not all required revision and 7 were
successfully treated with antibiotics. Infection, however,
was the major cause of implant failure in the MI patient
group. In the MI group, five cases of infection occurred
prior to any implant lengthening procedures. Of the
remaining eight infections reported, four occurred after
one lengthening procedure, two after two lengthening
procedures and one after three lengthening procedures.
In the remaining infected case, the time of the reported
infection had not been recorded. Of these infections, nine
MI (35%) implants were revised due to septic loosening
(two cemented and seven uncemented implants), whereas
only one (11%) NI implant was revised due to infection.
Of the nine MI implants revised, eight of these implants
had been lengthened and consisted of one cemented prox-
imal tibial, one uncemented proximal humeral, one unce-
mented proximal femoral and four uncemented and one
cemented distal femoral replacement implants. The unce-
mented proximal tibial NI implant was revised due to
infection following three lengthening procedures. Failed
two-stage revision surgery was carried out on the infected
NI prosthesis and two of the infected MI prostheses and all
eventually resulted in amputation. The mean time until
infection was 15.5 months in the NI group and 19.2
Figure 1. Reasons for implant removal in the MI patient group. MI: minimally invasive.
Figure 2. Reasons for implant removal in the NI patient group.
NI: non-invasive.
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months in the MI group with no significant difference
found between the two sets of data.
Aseptic loosening
None of the NI implants failed due to aseptic loosening;
however, six (23%) MI implants were revised for aseptic
loosening of the intramedullary stem (three were cemented
and three uncemented stems). These six revision surgeries
occurred at 14-, 19-, 22-, 28-, 39- and 47-month post-limb
salvage. Four patients received a distal femoral replace-
ment, one a proximal tibial replacement and one a proximal
humeral replacement. Two of the four distal femoral repla-
cements failed due to loosening of the tibial component
where one was cemented and the other uncemented. The
remaining two distal femoral prostheses failed due to loos-
ening of the uncemented femoral intramedullary stem.
Both the proximal humeral and proximal tibial replace-
ments failed due to loosening of the cemented stem.
Full extension
Four (15%) MI implants were revised due to full extension
where further growth of the limb was required. However,
five (56%) of the failed NI implants were revised due to full
extension.
Lengthening failure
Mean implant lengthening in the MI group was 37 mm
(range, 10–130 mm), which required a mean of three
lengthening procedures (range, 1–9). In the NI patient
group, implants were lengthened to a mean of 21 mm
(range, 0–88), which required a mean of four lengthening
procedures (range, 1–10). The mean length achieved during
each lengthening episode in the MI group was 14 mm
(range, 8–21 mm) and 5 mm (range, 1–11 mm) in the NI
patient group. Twenty-six MI and 22 NI prostheses were
not lengthened with the main reasons being poor patient
condition, early death or amputation. One implant in the MI
group (11%) and three (33%) in the NI group were revised
following failure of the gearbox. The failures in the NI
group occurred soon after the introduction of the device
and manufacturing and testing protocols were then put in
place, which resulted in no further failure. Four (15%) MI
implants were revised due to prosthetic collapse.
Amputation and nerve palsy
Two patients (3.2%) in the MI group underwent amputation
due to tumour recurrence and irreversible ischemia where
both resulted in an above the knee amputation. Five
patients with distal femoral prostheses (four MI and one
NI) demonstrated poor range of knee motion that was made
worse after implant extension and resulted in fixed flexion
deformities. A patient implanted with an MI prosthesis
suffered a common peroneal nerve palsy after a
lengthening episode (15 mm); however, this patient recov-
ered to full function after 13 months. No patients with NI
endoprostheses reported nerve palsies.
Implant fracture
One MI proximal tibial prosthesis fractured 15-month post
implantation following a fall. This prosthesis was revised to
another MI prosthesis.
Survival analysis
Kaplan–Meier analysis showed the probability of an MI
bone tumour implant surviving with respect to implant
revision due to implant failure for any cause and at a
mean follow-up of 49 months was 58.8%. The survival
of an NI implant at a mean of 22 months was 78.6%. No
significant difference in overall survivorship between
these two patient groups was found (Figure 3). Implant
survival in the NI patient group at 1-year post operation
was 97.1 + 2.8% compared with 96.7 + 2.3% in MI
patients. At 7-year post-surgery implant, survivorship
had decreased to 40.4 + 14.4% in the NI group and
45.0 + 7.9% in the MI patient group. If full extension
was removed from the data as a form of implant failure,
survivorship analysis demonstrated that at 7-year post
operatively, NI prostheses had a survival rate of 76.3%
and MI prostheses a survival of 49.0%.
Implant survivorship analysis with infection as the
endpoint showed a significant difference between groups
(p ¼ 0.042; Figure 4). Only one NI implant failed due to
infection at 20-month post-surgery giving a survival of
94.4% + 5.4% over the study period of 7 years. The
Figure 3. Kaplan–Meier survival analysis with respect to implant
revision due to implant failure for any cause.
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probability of failure due to infection in the MI patient
group decreased from 98.3 + 1.7% at 1-year post-
surgery to 76.2+ 8.3% at 7-year post-surgery.
Full extension accounted for 56% of NI prosthetic fail-
ures and 15% of MI implant failures (p ¼ 0.005). Kaplan–
Meier analysis of implant survivorship with full extension
as the endpoint showed that at 1-year post-surgery,
implant survival was 96.7+ 3.3% in the NI patient group
and 94.8+ 2.9% for MI prostheses. At 7-year post oper-
ation, MI implants demonstrated a survival rate of 76.3+
11.1% and NI implants 49.5 + 7.9% (Figure 5).
Discussion
Earlier designs of extendible prostheses were modular,
where the midsection of the implant was exchanged for
progressively longer sections. These designs required large
surgical incisions to exchange the extension parts. There-
fore, implants were superseded by MI designs, which
required a small incision under anaesthesia to expand the
prostheses. Expansion of these implants increased the risk
of anaesthetic complications and infection and NI designs
were introduced in the 1990s. Our study investigated sur-
vival of the Stanmore MI and NI extendible prostheses over
a period of 16 years. Patient survival compared favourably
with other studies that have investigated the use of extend-
ible endoprostheses2,3,5,10 and our results found no statisti-
cally significant difference in overall implant survival
when the two groups were compared. The commonest rea-
son for failure of MI endoprostheses was peri-implant
infection, whereas full extension was the main reason for
NI implant revision surgery.
Deep infection after endoprosthetic replacement of a
bone tumour is a major complication associated with sig-
nificant morbidity, increased number of surgical proce-
dures, prolonged rehabilitation, pain, worse functional
outcome and revision surgery, where failure of revision can
result in amputation. Factors that increase infection include
radiation therapy, ‘maintenance surgery’ (e.g. bushing
replacement), patellar procedures and anatomic site (par-
ticularly involvement of the tibia).11 Infection has also been
associated with difficulty in obtaining soft tissue coverage
of the prostheses following limb reconstruction, which is
more problematic in proximal tibial replacements.12 These
factors combined with the size of the implant, the peri-
operative time and immunosuppression associated with
chemotherapy6 may explain why six patients (five MI and
one NI) developed an infection within 7 months of surgery
and before any invasive limb lengthening procedures had
taken place. This study identified an infection rate of 9.52%
in the NI implant group and 20.97% in the MI patient
group, which is similar to previous studies where infection
rates were measured ranging from 4%13 up to 40%.3 In our
study, 8 of the 13 reported MI infections occurred after the
lengthening procedures had begun and all 8 of these
implants were revised. Jeys et al.11 reported an increased
infection risk of 0–5% with each MI lengthening. Grimer
et al.14 reported 5 lengthening-associated infections in a
study of 20 patients with extendable tibial prostheses, while
studies by Ayoub et al.15 and Eckardt et al.16 noted no
lengthening-related infections. In our study, most infec-
tions appeared after one lengthening procedure with fewer
infections noted after three lengthening procedures. How-
ever, a study by Hantes et al.17 reported an increased inci-
dence and severity of complications (including infection)
Figure 4. Kaplan–Meier survival analysis with respect to implant
revision due to infection.
Figure 5. Kaplan–Meier survival analysis with respect to implant
revision due to full extension.
Coathup et al. 5
with increases in lengthening and a retrospective study by
Eckardt et al.16 demonstrated significant complications in
56% of patients with extendible prostheses, although this
study also showed that the lengthening procedures
themselves did not cause any infections. The NI implants
investigated in this study were inserted more recently
(2002–2010) when compared with MI implants and it is
possible that the difference in infection rates may also in
part be due to the benefits from recent advances in hospi-
tal infection control and patient management. It may also
be due to the relatively recent use of a gastrocnemius flap
during surgery, which has been shown to decrease the rate
of infection in limb salvage procedures.12 However, in our
study, gastrocnemius flaps were used in every case.
Silver-coated implants have demonstrated good antimi-
crobial activity and have been introduced into oncological
musculoskeletal surgery with success18; however, in this
study, none of the NI or MI implants investigated were
silver-coated.
Full extension where growth of the limb was still
required was the main long-term complication resulting
in revision of NI implants. These findings are similar to
those reported by Sewell et al.8 who also found that full
extension was a major reason for revision surgery. This
may be due to the NI prostheses having a lower lengthening
capacity compared with MI prostheses, which is due to the
extra size associated with the magnet and gearbox. As full
extension is not necessarily ‘implant failure’, when these
results were excluded, survivorship analysis demonstrated
that at 7-year post operatively, NI prostheses had a higher
survival rate of 76.3% when compared with MI prostheses
(49.0%). Complications that may interrupt long-term suc-
cess due to early revision of an NI implant following full
extension are unknown. Optimal fixation of the implant
within bone is essential and, therefore, if both bone quality
and quantity are sufficient, then it is possible that implant
success would not be further compromised. A recent study
investigated the use of NI implants for the revision of pre-
vious endoprostheses and reported it to be a successful
option in the mid-term with a revision-free implant survival
of 75% at 2 years reducing to 55% at 5 years.19 Neverthe-
less, further investigation is required to establish factors
that affect the long-term survival of these implants follow-
ing both primary and revision surgery.
Aseptic loosening of extendible massive bone tumour
endoprostheses is also a major complication causing
implant failure. Increased bone resection levels following
distal femoral and proximal tibial implant surgery are asso-
ciated with increased rates of aseptic loosening20 and
results from our study found a 23%MI loosening rate with
no NI failures, despite NI patients having a significantly
larger mean bony resection level. Prosthetic aseptic loosen-
ing is a mid-term complication and has been reported to
occur within 3–9 years after primary surgery.21,22 There-
fore, in our study, it is possible that aseptic loosening of MI
prostheses may be increased when compared with NI pros-
theses due to the longer follow-up period.
Lengthening procedures confer a significant improve-
ment in the functional score of growing patients.10 In our
study, some implants were not lengthened (48/105), with
the main reasons being poor general condition, early
death or amputation. Fifty-four percent of implants were
lengthened and this is similar to lengthening rates
reported in the literature (50–75%).16,23 Gearbox failure
or a collapsed lengthening mechanism resulted in failure
in both groups. Early physiotherapy may prevent exten-
sive tissue scarring which may reduce the force exerted
on the gearbox during lengthening. The results reported
in this study are relatively short-term but show that NI
implants may reduce the incidence of decreased ROM
and nerve palsies as shorter lengthening episodes can
occur more often.
A limitation of this study is the relatively small number
of patients in each of the surgical reconstruction groups
as only 50 paediatric patients are treated for sarcoma
with limb salvaging techniques per year in the United
Kingdom.24 A second limitation is that this study was car-
ried out retrospectively with analysis of patients over a
relatively short postoperative follow-up period. A recent
study by Gilg et al.25 investigated a similar number of NI
extendible implants but at a longer mean follow-up time of
64 months. This study reported a higher implant infection
rate (19.6%) and it is conceivable that this difference in
outcome may in part be due to our shorter post-surgical
follow-up window. In this study, variation was minimized
as all implants were made by a single manufacturer. Surgi-
cal techniques and patient care were also consistent as all
patients were treated at a single institution. MI prostheses
are infrequently used at our hospital and results showed that
infection (35%) was significantly higher when compared
with NI patients (11%). However, at the follow-up period
investigated in this study and when all reasons for failure
were taken into account, overall implant survival was rel-
atively low in both groups and it is important to consider
that rates of implant infection are expected to further
increase in both patient cohorts following revision
surgery.26 Lengthening of NI prostheses is painless, can
be carried out in the clinic and in cases where multiple
lengthening procedures are required, it may be more cost-
effective as unlike MI lengthening, it does not require hos-
pitalization, a general anaesthetic and additional surgery.
However, to accommodate an NI implant, the amount of
bone resected during primary surgery may be increased and
further work is required to improve the amount of growth
potential available in these implants.
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